Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
Why Shares in Novo Nordisk Soared This Week
Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.
Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months
Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders
The weight loss drug market may reach $95 billion within five years.
Viking Therapeutics, Inc. ( VKTX ) Stock Falls Amid Market Uptick: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) reached $24.09 at the closing of the latest trading day, reflecting a -2.92% change compared to its last close.
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.
This Under-the-Radar Healthcare Stock Could Soar in 2026
We should know a lot more by year-end.
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
One of them is already a leader in the market for weight management drugs, and the other could join this field.
Where Does VKTX Stock Stand After the Obesity Pill Setback?
Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
Peering Into Viking Therapeutics's Recent Short Interest - Viking Therapeutics ( NASDAQ:VKTX )
Viking Therapeutics's VKTX short percent of float has fallen 4.11% since its last report. The company recently reported that it has 27.51 million shares sold short, which is 29.36% of all regular shares that are available for trading.
Wall Street Bulls Look Optimistic About Viking Therapeutics ( VKTX ) : Should You Buy?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Viking Therapeutics, Inc. ( VKTX ) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.48, indicating a -5.56% shift from the previous trading day.
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.
Jim Cramer Expects Palantir To Reach New All-Time High - Lear ( NYSE:LEA ) , Lumen Technologies ( NYSE:LUMN )
Cramer still expects Palantir going to $200. Jim Cramer says no to Viking Therapeutics. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic ...
Down 34%, Should You Buy the Dip on Viking Therapeutics?
Viking aims to enter the billion-dollar weight loss drug market.
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years
Both companies have made significant progress in recent years.
The Problem With Weight Loss Stocks
There are new ways to tackle weight loss, but the stocks leading the way are lagging.
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Viking Therapeutics, Inc. ( VKTX ) Suffers a Larger Drop Than the General Market: Key Insights
Viking Therapeutics, Inc. (VKTX) reached $27.05 at the closing of the latest trading day, reflecting a -1.92% change compared to its last close.
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
Investment bank analysts up and down Wall Street are pounding the table on these stocks.
Why Viking Therapeutics Stock Popped Nearly 4% Today
The company's obesity drug could have more potential than originally believed.
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock ( Hint: It's Not Eli Lilly or Novo Nordisk )
Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock.
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?
Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.
Why Is Viking Therapeutics Stock Crashing, and Is It a Buying Opportunity?
The market for weight loss treatments is growing significantly and is forecast to continue increasing for several years.
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
Viking Therapeutics: What's Next?
Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum.
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
These companies aren't performing as badly as their stock-market performances this year suggest.
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.
Bulls And Bears: Sunrun, Newegg, Walmart - And Powell Offers Rate Cut Hope Bulls And Bears: Sunrun, Newegg, Walmart - And Powell Offers Rate Cut Hope - Alibaba Gr Hldgs ( NYSE:BABA )
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories. Markets rallied sharply this week following Federal Reserve Chair Jerome Powell's dovish signals at the Jackson Hole symposium.
Viking Therapeutics ( VKTX ) Down 23.4% Since Last Earnings Report: Can It Rebound?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Shares in Viking Therapeutics Crashed This Week
The phase 2 trial results for its key drug didn't pan out quite as planned.
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?
Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and future prospects.
A Closer Look at Viking Therapeutics's Options Market Dynamics - Viking Therapeutics ( NASDAQ:VKTX )
Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we found 58% of traders were bullish, while 33% showed bearish tendencies.
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?
A disappointing result for its oral obesity candidate hammered the stock price.
Here's Why Viking Therapeutics Bounced Back Today
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.
Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.
Wall Street Analysts Think Viking Therapeutics ( VKTX ) Is a Good Investment: Is It?
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Viking's 42% Plunge Splits Experts-A '$129 Strong Buy' Or 'Clearly Inferior' Drug? - Viking Therapeutics ( NASDAQ:VKTX )
Viking Therapeutics Inc. VKTX saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts. ArrivedBuy shares of homes and vacation rentals for as little as $100.
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme' - Viking Therapeutics ( NASDAQ:VKTX )
Viking stock dropped after Phase 2 obesity pill data showed higher discontinuations. William Blair kept an Outperform rating, calling the sell-off excessive. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Eli Lilly ( NYSE:LLY )
Novo's pill requires ~75 times more active ingredient per week than Wegovy injections. Lilly has $808.5 million in orforglipron inventory ahead of its planned 2026 launch. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Tech Stocks Drop, Palantir Plunges 8%: Markets Today - Palantir Technologies ( NASDAQ:PLTR )
Nasdaq 100 sinks 1.4%, its worst session in two weeks, as tech stocks lead Wall Street's pullback. Cryptos erase $110 billion; Bitcoin slides below its 50-day average, Ethereum falls 4.5%. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, ...
